Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIRINOX
- Development stage
- Phase 3
- Lead developer
- Wakayama Medical University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FIRINOX is a modified chemotherapy regimen developed by Wakayama Medical University for the neoadjuvant treatment of borderline resectable pancreatic ductal carcinoma. It is a simplified version of the standard FOLFIRINOX protocol, consisting of oxaliplatin, irinotecan, and continuous infusion fluorouracil (5-FU). The modification involves the removal of leucovorin (folinic acid) and the 5-FU bolus, alongside a dose reduction of irinotecan to 150 mg/m2. These changes are intended to mitigate the high rates of grade 3/4 neutropenia and gastrointestinal toxicities associated with standard FOLFIRINOX while maintaining therapeutic efficacy in the preoperative setting.
- Other names
- modified FOLFIRINOXFIRINOX regimen
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on FIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIRINOX.